LEXINGTON, Mass., April 27, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, will release
its first quarter 2017 financial results before the market opens on
Thursday, May 4, 2017. Agenus
executives will host a conference call at 11:00 a.m. ET the same day.
To access the live call, dial 1-844-492-3727 (U.S.) or
1-412-317-5118 (international) and ask to be joined into the Agenus
call. The call will also be webcast and will be accessible from the
company's website at www.agenusbio.com/webcast. A replay
will be available on the Company's website approximately two hours
after the call and will remain available for 90 days.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing a number of combination
approaches that leverage a broad repertoire of antibody
therapeutics and proprietary cancer vaccine platforms. The Company
is equipped with a suite of antibody discovery platforms and a
state-of-the-art GMP manufacturing facility with the capacity to
support early phase clinical programs. Agenus is based in
Lexington, MA. For more
information, please visit www.agenusbio.com; information that may
be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding Agenus' anticipated timing for releasing its
first quarter 2017 financial results. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:
Agenus Inc.
Michelle Linn, 781-674-4541
Agenus Inc. michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-report-first-quarter-2017-financial-results-on-may-4-2017-conference-call-to-follow-300446858.html
SOURCE Agenus Inc.